Page 6 - Sequenom Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dublin, March 17, 2022 (GLOBE NEWSWIRE) -- The "Non-invasive Prenatal Testing Global Market Report 2022, By Type, By End User, By Instruments, By...

* Not for trading, but in connection with the registration of American Depositary Shares, pursuant to the requirements of the Securities and Exchange Commission. Securities registered or to be registered pursuant to Section 12(g) of the Act: None None Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report: Title of each class Ordinary Shares, nominal value £0.0025 per Share 131,467,935 Indicate by check mark if the registrant is a...

EXECUTIVE CHANGES: New CFOs for Sensyne, Focusrite, Bango, 4D Pharma Mon, 1st Mar 2021 16:41 (Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and not separately reported by Alliance News: Sensyne Health PLC - Oxford, England-based clinical technology using artificial intelligence - Moves Chief Investment Officer Richard Pye to chief financial officer and executive director, while interim CFO Michael Norris moves to non-executive director, both from last Friday. Norris has been interim CFO since March last year. Additionall...

Insilico Medicine discovers novel preclinical candidate to address idiopathic pulmonary fibrosis Insilico Medicine has demonstrated a breakthrough in Artificial Intelligence ("AI") and drug discovery -- linking together generative chemistry and biology for the first time -- to discover a novel preclinical candidate addressing idiopathic pulmonary fibrosis ("IPF") and be validated with multiple human cell and animal model experiments. Often found implicated in a wide range of diseases and multiple organs such as lung, liver and kidney, IPF addresses a very broad medical need that affects hundr...

Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI Insilico Medicine Achieves Industry First Nominating Preclinical Candidate for Idiopathic Pulmonary Fibrosis With Both Novel Drug Target and Novel Molecule Discovered by Artificial Intelligence HONG KONG, Feb. 24, 2021 /PRNewswire/ -- Insilico Medicine has demonstrated a breakthrough in Artificial Intelligence ("AI") and drug discovery - linking together generative chemistry and biology for the first time - to discover a novel preclinical candidate addressing idiopathic pulmonary fibrosis ("IPF") and ...